Thousand Oaks, California, United States www.amgen.com
2021 Revenues ($USD) : $25,979,000,000 2021 R&D spend : $4,819,000,000 2021 Number of Employees : 24,200 Fiscal Year End : 12/31/2021 Leader : CEO Robert Bradway
[Container closure integrity (CCI) testing of syringes in the device and packaging engineering lab. Image courtesy of Amgen.]
Amgen’s revenues grew 2% in 2021, hitting a company record of $26 billion. The Thousand Oaks, California–based company scored two notable FDA approvals. Lumakras/Lumykras became the first medicine to win approval for KRAS G12C-mutated non-small cell lung cancer. In December 2021, Tezsire became the first FDA-approved biologic for severe asthma without a phenotype or biomarker limitation within its approved label. Also in 2021, the company won an expanded indication for Otezla (apremilast) to treat adults with plaque psoriasis, regardless of severity level. In November 2021, Amgen was named to the Dow Jones Sustainability World Index for the eighth consecutive year. The company aims to become carbon neutral by 2027 and reduce water use by 40% and waste disposal by 75% in the same time frame. —BB
Tell Us What You Think!
You must be logged in to post a comment.